EAM
KYNB

Eventide Asset Management’s Kyntra Bio KYNB Stock Holding History

Eventide Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,400
Closed -$17.9M – 147
2023
Q1 		$17.9M Buy
+38,400
New +$20.3M 0.33% 90

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's KYNB Position: Q2 2023 in Review

Eventide Asset Management sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 38,400 shares — an estimated $17.9M sold.

Eventide Asset Management first reported a position in KYNB in Q1 2023 and held it in 1 quarter. The position peaked at $17.9M in Q1 2023. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Eventide Asset Management reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Eventide Asset Management sold 38,400 Kyntra Bio shares in Q2 2023, an estimated $17.9M.
  • Eventide Asset Management first reported a position in Kyntra Bio in Q1 2023 and held it in 1 quarter.
  • Eventide Asset Management's Kyntra Bio position peaked at $17.9M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.